Usefulness of I-FABP in the diagnosis and follow-up of celiac disease.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON23786

Enrollment

225

Registered

2011-01-11

Start date

2010-03-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

celiac disease, I-FABP, diagnosis, non-invasive, human leukocyte antigen (HLA)

Interventions

All children with positive celiac disease screening and elevated plasma I-FABP levels will start a gluten-free diet, independent of duodenal histology, since patients with positive celiac screening bu

Eligibility

Inclusion criteria

Inclusion criteria: 1. Clinical suspicion of celiac disease and/or positive celiac disease screening (tissue transglutaminase (tTG), endomysium (EMA) or gliadine (AGA) antibodies); 2. Age between 6 months and 18 years.

Exclusion criteria

Exclusion criteria: History of inflammatory bowel disease.

Design outcomes

Primary

Measure	Time frame
The usefulness of I-FABP plasma levels for diagnosing celiac disease in children with enhanced titres of tTG, EMA or AGA antibodies and genetic predisposition.	—

Secondary

Measure	Time frame
1. Value of recovery of I-FABP levels in response to a gluten-free diet; 2. Value of urine I-FABP levels.	—

Contacts

Public ContactA.C.E. Vreugdenhil

Maastricht University Medical Center Department of Pediatrics Postbus 5800

a.vreugdenhil@mumc.nl+31 (0)43 3875282

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)